Literature DB >> 22884877

LANP mediates neuritic pathology in Spinocerebellar ataxia type 1.

Marija Cvetanovic1, Rupinder K Kular, Puneet Opal.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disease that results from a pathogenic glutamine-repeat expansion in the protein ataxin-1 (ATXN1). Although the functions of ATXN1 are still largely unknown, there is evidence to suggest that ATXN1 plays a role in regulating gene expression, the earliest process known to go awry in SCA1 mouse models. In this study, we show that ATXN1 reduces histone acetylation, a post-translational modification of histones associated with enhanced transcription, and represses histone acetyl transferase-mediated transcription. In addition, we find that depleting the Leucine-rich Acidic Nuclear Protein (LANP)-an ATXN1 binding inhibitor of histone acetylation-reverses aspects of SCA1 neuritic pathology.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884877      PMCID: PMC3987943          DOI: 10.1016/j.nbd.2012.07.024

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  43 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Functions of site-specific histone acetylation and deacetylation.

Authors:  Mona D Shahbazian; Michael Grunstein
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

Review 3.  Trinucleotide repeat disorders.

Authors:  Harry T Orr; Huda Y Zoghbi
Journal:  Annu Rev Neurosci       Date:  2007       Impact factor: 12.449

4.  Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1.

Authors:  X Lin; B Antalffy; D Kang; H T Orr; H Y Zoghbi
Journal:  Nat Neurosci       Date:  2000-02       Impact factor: 24.884

5.  ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.

Authors:  Yung C Lam; Aaron B Bowman; Paymaan Jafar-Nejad; Janghoo Lim; Ronald Richman; John D Fryer; Eric D Hyun; Lisa A Duvick; Harry T Orr; Juan Botas; Huda Y Zoghbi
Journal:  Cell       Date:  2006-12-29       Impact factor: 41.582

6.  Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation.

Authors:  Bernd O Evert; Julieta Araujo; Ana M Vieira-Saecker; Rob A I de Vos; Sigrid Harendza; Thomas Klockgether; Ullrich Wüllner
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

7.  The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7.

Authors:  Jennifer R Gatchel; Kei Watase; Christina Thaller; James P Carson; Paymaan Jafar-Nejad; Chad Shaw; Tao Zu; Harry T Orr; Huda Y Zoghbi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-23       Impact factor: 11.205

Review 8.  CAG repeat disorder models and human neuropathology: similarities and differences.

Authors:  Mitsunori Yamada; Toshiya Sato; Shoji Tsuji; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2007-09-05       Impact factor: 17.088

9.  The role of LANP and ataxin 1 in E4F-mediated transcriptional repression.

Authors:  Marija Cvetanovic; Robert J Rooney; Jesus J Garcia; Nataliya Toporovskaya; Huda Y Zoghbi; Puneet Opal
Journal:  EMBO Rep       Date:  2007-06-08       Impact factor: 8.807

10.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin.

Authors:  J M Boutell; P Thomas; J W Neal; V J Weston; J Duce; P S Harper; A L Jones
Journal:  Hum Mol Genet       Date:  1999-09       Impact factor: 6.150

View more
  13 in total

Review 1.  Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Janghoo Lim
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

2.  Mutant Ataxin-1 Inhibits Neural Progenitor Cell Proliferation in SCA1.

Authors:  Marija Cvetanovic; Yuan-Shih Hu; Puneet Opal
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

3.  An out-of-frame overlapping reading frame in the ataxin-1 coding sequence encodes a novel ataxin-1 interacting protein.

Authors:  Danny Bergeron; Catherine Lapointe; Cyntia Bissonnette; Guillaume Tremblay; Julie Motard; Xavier Roucou
Journal:  J Biol Chem       Date:  2013-06-12       Impact factor: 5.157

4.  The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.

Authors:  Anand Venkatraman; Yuan-Shih Hu; Alessandro Didonna; Marija Cvetanovic; Aleksandar Krbanjevic; Patrice Bilesimo; Puneet Opal
Journal:  Hum Mol Genet       Date:  2014-03-04       Impact factor: 6.150

Review 5.  Pathogenic mechanisms underlying spinocerebellar ataxia type 1.

Authors:  Leon Tejwani; Janghoo Lim
Journal:  Cell Mol Life Sci       Date:  2020-04-18       Impact factor: 9.261

6.  Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes.

Authors:  Natalie M Frederick; Parth V Shah; Alessandro Didonna; Monica R Langley; Anumantha G Kanthasamy; Puneet Opal
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

7.  Developmental Alterations in Adult-Onset Neurodegenerative Disorders: Lessons from Polyglutamine Diseases.

Authors:  Chandrakanth Reddy Edamakanti; Puneet Opal
Journal:  Mov Disord       Date:  2021-05-20       Impact factor: 9.698

Review 8.  The promise and perils of HDAC inhibitors in neurodegeneration.

Authors:  Alessandro Didonna; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2014-12-03       Impact factor: 4.511

9.  Targeted ANP32E mutant mice do not demonstrate obvious movement defects.

Authors:  Peiyan Wong; Vonny I Leo; Meijun Low; Tak W Mak; Xiaodong Zhang; Patrick T Reilly
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

10.  Inhibition of Vascular Endothelial Growth Factor Receptor 2 Exacerbates Loss of Lower Motor Neurons and Axons during Experimental Autoimmune Encephalomyelitis.

Authors:  Milos Stanojlovic; Xiaosha Pang; Yifeng Lin; Sarrabeth Stone; Marija Cvetanovic; Wensheng Lin
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.